Lifestars is a celebration of the success stories, innovations, transformational deals and the people, teams and organisations that play such a critical role in the advancement of the life sciences industry over the last 12 months across Europe.
The international awards bring together hundreds of global life science leaders, investors and deal makers and key stakeholders from the wider eco-system to recognise the achievements of the industry. 19 awards were contested during a prestigious gala dinner hosted at the Honourable Artillery Company in London, UK on the 19th November. The Awards supported Teenage Cancer Trust as the official Charity beneficiary.
European Lifestars Awards™ forms a signature, evening networking function during the Inv€$tival Showcase and Jefferies Annual Healthcare Conference week in London, Europe's largest healthcare investment banking conference.
Neil Darkes, Co-CEO, LSX Ltd and Lifestars commented:
“Lifestars presents a fantastic opportunity to bring together a deserved audience and highlight the advances being made in our industry. It’s testament to Sensyne Health’s efforts that this year’s judging faculty have recognised them in this manner."
Lord (Paul) Drayson PhD, CEO of Sensyne Health plc, said:
“We are delighted to be honoured with this award in recognition of our unique business model that directly pays back to the NHS, and our novel approach in maximizing the potential of ethically sourced anonymised data to benefit patients.”
The Lifestars™ Awards are organised by LSX, an influential community of senior life science decision makers. Through impactful events, powerful thought leadership content and unique networking opportunities, LSX exists to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare. For more information please visit www.lsxleaders.com/lifestars-awards
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).